Dr. Rogawski is distinguished professor of neurology and pharmacology at the University of California, Davis. He teaches in the UC Davis School of Medicine and is on the active medical staff of UC Davis Health. He is an affiliate member of the UC Davis Center for Neuroscience. |
|
News
CURE Epilepsy Lecture
On November 30, 2022, Dr. Rogawski presented a seminar at Texas A & M University College of Medicine that was supported by CURE Epilepsy as part the CURE Epilepsy Frontiers in Epilepsy Research Seminar Series. The title of the presentation was: "Role of AMPA Receptors in Epilepsy and as a Target for Antiseizure Medications."
On November 30, 2022, Dr. Rogawski presented a seminar at Texas A & M University College of Medicine that was supported by CURE Epilepsy as part the CURE Epilepsy Frontiers in Epilepsy Research Seminar Series. The title of the presentation was: "Role of AMPA Receptors in Epilepsy and as a Target for Antiseizure Medications."
National Academy of Inventors
Dr. Rogawski was elected as a fellow of the National Academy of Inventors on December 8, 2020. He was inducted at the NAI 10th Annual Meeting October 31 – November 3, 2021 in Tampa, Florida. A news story is available here.
Dr. Rogawski was elected as a fellow of the National Academy of Inventors on December 8, 2020. He was inducted at the NAI 10th Annual Meeting October 31 – November 3, 2021 in Tampa, Florida. A news story is available here.
China Association Against Epilepsy
On October 23, 2020, Dr. Rogawski presented an invited lecture to the China Association Against Epilepsy, a chapter of the ILAE. The topic was "AMPA receptors in epilepsy and as targets for antiepileptic drugs." There were 300 epilepsy physicians in attendance and almost 4,000 epilepsy physicians participated online.
On October 23, 2020, Dr. Rogawski presented an invited lecture to the China Association Against Epilepsy, a chapter of the ILAE. The topic was "AMPA receptors in epilepsy and as targets for antiepileptic drugs." There were 300 epilepsy physicians in attendance and almost 4,000 epilepsy physicians participated online.
Antiseizure Drugs
Michael A. Rogawski in Basic and Clinical Pharmacology, 15th Edition, edited by Bertram G. Katzung and Todd W. Vanderah. Published by McGraw-Hill Education, 2021.
Michael A. Rogawski in Basic and Clinical Pharmacology, 15th Edition, edited by Bertram G. Katzung and Todd W. Vanderah. Published by McGraw-Hill Education, 2021.
Back from the Depths of Postpartum Depression
Allopregnanolone (brexanolone) is in clinical use at UC Davis Medical Center.
Allopregnanolone (brexanolone) is in clinical use at UC Davis Medical Center.
The 2019 Theodore Koppanyi Lectureship in Pharmacology
On June 4, 2019, Dr. Rogawski presented the annual Theodore Koppanyi Lectureship in Pharmacology & Physiology at Georgetown University on the topic of "Neuroactive Steroids for the Treatment of Neurological and Psychiatric Disease."
On June 4, 2019, Dr. Rogawski presented the annual Theodore Koppanyi Lectureship in Pharmacology & Physiology at Georgetown University on the topic of "Neuroactive Steroids for the Treatment of Neurological and Psychiatric Disease."
UC Davis Chancellor's Innovator of the Year Award
On May 30, 2019, Dr. Rogawski received the Innovator of the Year award "for his groundbreaking research with allopregnanolone, also known as brexanolone. Earlier this year, brexanolone received Food and Drug Administration approval as the first and only specific drug treatment for women with postpartum depression."
On May 30, 2019, Dr. Rogawski received the Innovator of the Year award "for his groundbreaking research with allopregnanolone, also known as brexanolone. Earlier this year, brexanolone received Food and Drug Administration approval as the first and only specific drug treatment for women with postpartum depression."
Faculty Opinions (formerly F1000) Faculty Member for Pharmacology & Drug Discovery
Since October 16, 2017, Dr. Rogawski has served as an F1000 faculty member. Dr. Rogawski's commentaries are available here.
Since October 16, 2017, Dr. Rogawski has served as an F1000 faculty member. Dr. Rogawski's commentaries are available here.
Election to AAAS Fellow
In October 2018, the American Association for the Advancement of Science elected Dr. Rogawski as a Fellow in the Section on Neuroscience. “Election as a Fellow honors AAAS members whose efforts on behalf of the advancement of science or its applications in service to society have distinguished them among their peers and colleagues.”
In October 2018, the American Association for the Advancement of Science elected Dr. Rogawski as a Fellow in the Section on Neuroscience. “Election as a Fellow honors AAAS members whose efforts on behalf of the advancement of science or its applications in service to society have distinguished them among their peers and colleagues.”
Jasper's Basic Mechanisms of the Epilepsies
Following a successful planning meeting in Yosemite National Park, March 4-8, 2019, the creation of the Fifth Edition of Jasper's Basic Mechanisms of the Epilepsies, often called the "bible of basic epilepsy research," is in progress.
Following a successful planning meeting in Yosemite National Park, March 4-8, 2019, the creation of the Fifth Edition of Jasper's Basic Mechanisms of the Epilepsies, often called the "bible of basic epilepsy research," is in progress.
Future of Epilepsy Therapy Discovery
Dr. Rogawski was an invited speaker in the session on Targeted Therapy at the 13th European Congress on Epileptology, Vienna, Austria, August 28, 2018. The topic of his presentation was "Targeting Novel Receptors."
Dr. Rogawski was an invited speaker in the session on Targeted Therapy at the 13th European Congress on Epileptology, Vienna, Austria, August 28, 2018. The topic of his presentation was "Targeting Novel Receptors."
Are Migraine and Seizure Related?
Answers by Michael Rogawski in BrainFacts.org, a public information initiative of the Society for Neuroscience. Published August 2, 2018.
Answers by Michael Rogawski in BrainFacts.org, a public information initiative of the Society for Neuroscience. Published August 2, 2018.
Treatment of Seizure Disorders
Michael A. Rogawski in Brody's Human Pharmacology: Mechanism-Based Therapeutics, 6th Edition edited by Lynn Wecker. Published by Elsevier, 2019.
Michael A. Rogawski in Brody's Human Pharmacology: Mechanism-Based Therapeutics, 6th Edition edited by Lynn Wecker. Published by Elsevier, 2019.
Gut Microbiome and the Ketogenic Diet
Dr. Rogawski quoted in Proceedings of the National Academy of Sciences Journal Club (June 28, 2018) in reference to the publication: Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 2018;173:1728-1741.
Dr. Rogawski quoted in Proceedings of the National Academy of Sciences Journal Club (June 28, 2018) in reference to the publication: Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 2018;173:1728-1741.
Epilepsy Foundation Research Roundtable for Epilepsy
Dr. Rogawski was an invited speaker at the Epilepsy Foundation's Research Roundtable for Epilepsy: Evolving Concepts in Endpoints and Populations in Epilepsy Trials, which was held at the American Institute of Architects, Washington, DC, May 17-18, 2018. The topic of his presentation was "Anti-ictal Versus Mechanism Targeted Therapies."
Dr. Rogawski was an invited speaker at the Epilepsy Foundation's Research Roundtable for Epilepsy: Evolving Concepts in Endpoints and Populations in Epilepsy Trials, which was held at the American Institute of Architects, Washington, DC, May 17-18, 2018. The topic of his presentation was "Anti-ictal Versus Mechanism Targeted Therapies."
UC DCC – University of California Drug Discovery Consortium
Dr. Rogawski is principal investigator of the UC DCC, funded by a UC Multicampus Research Programs and Initiatives grant from the University of California Office of the President. UC DCC provides access to drug discovery resources throughout the campuses of the University of California. UC DCC sponsors a grant program; information is available here.
Dr. Rogawski is principal investigator of the UC DCC, funded by a UC Multicampus Research Programs and Initiatives grant from the University of California Office of the President. UC DCC provides access to drug discovery resources throughout the campuses of the University of California. UC DCC sponsors a grant program; information is available here.
Treating Epilepsy’s Toughest Cases
Current medicines fail to relieve seizures in about a third of people with epilepsy. What can be done?
Scientific American
By David Noonan on April 1, 2017
Current medicines fail to relieve seizures in about a third of people with epilepsy. What can be done?
Scientific American
By David Noonan on April 1, 2017
Dr. Rogawski was a member of the faculty of the workshop on Refractory Status Epilepticus: Mechanisms and Management at the 141st Annual Meeting of the American Neurological Association, Baltimore Marriott Waterfront Hotel, September 18, 2016.
|
A story in Neurology Reviews describes Dr. Rogawski's presentation in the workshop [Neurology Reviews 2016 December;24(12):36]
|
Dr. Rogawski spoke on "Allopregnanolone Potential in the Treatment of Refractory and Super-refractory Status Epilepticus," in the session on Novel Therapies for Status Epilepticus at the 12th European Congress on Epileptology, Forum Hall, Prague Congress Centre, Kongresové centrum Praha, September 13, 2016.
Dr. Rogawski was an invited speaker at the 2016 Epilepsy Foundation Pipeline Conference in San Francisco, February 25-26, 2016.
Dr. Rogawski was an invited speaker at the 9th Annual Pain and Migraine Summit in Washington, DC., September 24-25, 2015.
Dr. Rogawski participated in the Ion Channel Symposium at Institute of Neuroscience, Zhejiang University, June 24, 2015.
|
Dr. Rogawski is the recipient of the American Academy of Neurology 2015 Neuroendocrine Research Award sponsored by the AAN and supported by friends of Dr. Andrew Herzog. The award was presented at the AAN 2015 Annual Meeting in Washington, D.C, April 18-25, 2015.
|
UC DAVIS MEDICINE, Volume 12, No. 1, Spring 2015, highlights spin-offs of Dr. Rogawski's research.
Dr. Rogawski has been appointed to the SIT (Science Innovation Team of International Scientific Experts) of EpLink, the Epilepsy Research Program of the Ontario Brain Institute, and he presented the keynote address at the 2015 EpLink Workshop on February 28, 2015 in Toronto.
Dr. Rogawski spoke at the University of Utah's ADD (Antiepileptic Drug Development) Program Symposium, Park City, Utah, May 17–20, 2015.
Dr. Rogawski spoke at Antiepileptic Drug and Device Trials XIII sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania Epilepsy Center and The Epilepsy Therapy Project, May 13–15, 2015, Turnberry Isle Miami, Aventura (North Miami Beach), Florida.
Dr. Rogawski spoke at the 5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures, April 9–11, 2015, Imperial College, London.
Dr. Rogawski spoke at the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, January 20–21, 2015, Keck Center of the National Academies, Washington, D.C. A summary of the workshop is available here.
Pediatric Super-refractory Status Epilepticus Treated with Allopregnanolone
Eileen Broomall, JoAnne E. Natale, Michele Grimason, Joshua Goldstein,
Craig M. Smith, Celia Chang, Stephen Kanes, Michael A. Rogawski, and Mark S. Wainwright
Annals of Neurology 76(6):911–915, 2014.
Allopregnanolone intravenous solution developed and manufactured at UC Davis Medical Center effectively treated two children with super-refractory status epilepticus, a life-threatening condition with high mortality and morbidity. One of the children, a 2 year-old girl, was a patient at the UC Davis Children's Hospital.
Some publications on neuroactive steroids and the treatment of status epilepticus are available here.
Eileen Broomall, JoAnne E. Natale, Michele Grimason, Joshua Goldstein,
Craig M. Smith, Celia Chang, Stephen Kanes, Michael A. Rogawski, and Mark S. Wainwright
Annals of Neurology 76(6):911–915, 2014.
Allopregnanolone intravenous solution developed and manufactured at UC Davis Medical Center effectively treated two children with super-refractory status epilepticus, a life-threatening condition with high mortality and morbidity. One of the children, a 2 year-old girl, was a patient at the UC Davis Children's Hospital.
Some publications on neuroactive steroids and the treatment of status epilepticus are available here.
Mechanisms of Action of Antiepileptic Drugs
Michael A. Rogawski and José Cavazos in Wyllie’s Treatment of Epilepsy, Sixth edition, edited by Elaine Wyllie, Barry E. Gidal, Howard P. Goodkin, Joseph I. Sirven, and Tobias Loddenkemper. Published by Wolters Kluwer, 2015.
Michael A. Rogawski and José Cavazos in Wyllie’s Treatment of Epilepsy, Sixth edition, edited by Elaine Wyllie, Barry E. Gidal, Howard P. Goodkin, Joseph I. Sirven, and Tobias Loddenkemper. Published by Wolters Kluwer, 2015.
Dr. Rogawski spoke at the Twelfth Eilat Conference on New Antiepileptic Drugs (EILAT XII), Madrid Spain, August 31 – September 3, 2014.
Research from the Rogawski laboratory led to two out of five drug products currently under development for the treatment of epilepsy. See discussion by Megan Culley in Drug development: Illuminated targets. Nature 2014 Jul 10;511(7508):S12–13.
Research from the Rogawski laboratory laid the groundwork for the first AMPA receptor antagonist available for clinical use. Some publications on AMPA receptors and the development of AMPA receptor antagonists for the treatment of epilepsy are available here.
A recent paper defines the blocking mechanism of the new AMPA receptor antagonist using patch clamp recording:
Chen CY, Matt L, Hell JW, Rogawski MA. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014 Sep 17;9(9):e108021. doi: 10.1371/journal.pone.0108021.
A recent paper defines the blocking mechanism of the new AMPA receptor antagonist using patch clamp recording:
Chen CY, Matt L, Hell JW, Rogawski MA. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014 Sep 17;9(9):e108021. doi: 10.1371/journal.pone.0108021.
Comment in Neurology Today
A publication of the American Academy of Neurology
A Small Proof of Concept Study Finds a “Rescue Inhaler” Could Benefit Photosensitive Epilepsy Patients
Polygenic Risk Scores May Help Identify Patients at Higher Risk of Common Types of Epilepsy
Polygenic Risk Scores May Help Identify Patients at Higher Risk of Common Types of Epilepsy
Research
The goal of our work is to discover and develop improved treatments for neurological disorders, including seizures and epilepsy, migraine, traumatic brain injury and neurobehavioral disorders. Click on images to access further information or representative publications.
The goal of our work is to discover and develop improved treatments for neurological disorders, including seizures and epilepsy, migraine, traumatic brain injury and neurobehavioral disorders. Click on images to access further information or representative publications.
Neurosteroid Research
AMPA Receptors
Headache
|
Antiseizure Drug Mechanisms
Allopregnanolone for TBI
Convection-enhanced Delivery
|
GABA Receptor
Glia and Epilepsy
Super-refractory SE
|